Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Chonnam Med J. 2000 Jun;36(2):179-185. Korean. Clinical Trial.
Cho KH , Kim MK , Kim TS , Kim BC , Lee SH , Hwang IY , Kim JT , Kim JK .
Department of Neurology, Chonnam National University Medical School, Kwangju, Korea.
Department of Neurosurgery, Chonnam National University Medical School, Kwangju, Korea.

Selegiline HCl (MAO-B(R)) is a levorotatory acetylenic derivative of phenethylamine. The drug is an enzyme-activated irreversible inhibitor of monoamine oxidase (MAO), also known as mechanism-based, kcat, or "suicide" inhibitor. We carried out an open, non-comparative clinical study prospectively to investigate whether the disability of patients with Parkinson's disease could be improved during the first 3 months by Selegiline (MAO-B : 5-10 mg/day). Selegiline (MAO-B ) has been administered as monotherapy or combination with levodopa. A clinical trial was conducted over 3 months with 23 patients in our hospital. Sym- ptomatology was assessed on Unified Parkinson's Disease Rating Scale (UPDRS). Results obtained to data, indicate that UPDRS score was significantly improved at the end of 3 months. Adverse effects were rare and minor. Therefore, this study confirmed that Selegiline (MAO-B ) has proved itself to be a safe and effective monotherapy or adjuvant in long-term levodopa therapy of Parkinson's disease.

Copyright © 2019. Korean Association of Medical Journal Editors.